Akcea and Ionis report positive data from phase 2 study of AKCEA-APO(a)-LRx
Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, announced positive topline results from a Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a). September 24, 2018